CytoSorbents (CytoSorbents) Total Current Assets : $19.99 Mil (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is CytoSorbents Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. CytoSorbents's total current assets for the quarter that ended in Mar. 2024 was $19.99 Mil.

CytoSorbents Total Current Assets Historical Data

The historical data trend for CytoSorbents's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents Total Current Assets Chart

CytoSorbents Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

20.90

82.45

64.30

33.76

25.70

CytoSorbents Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															28.17	23.64	19.26	25.70	19.99

CytoSorbents Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

CytoSorbents's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	14.131	+	6.057	+	3.68	+	1.835
	=	25.70

CytoSorbents's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	8.608	+	6.765	+	3.739	+	0.881
	=	19.99

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

CytoSorbents (NAS:CTSO) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

CytoSorbents's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.608	-	28.143	+	0.75 * 6.765	+	0.5 * 3.739
=	-12.59

CytoSorbents Total Current Assets Related Terms

Thank you for viewing the detailed overview of CytoSorbents's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoSorbents (CytoSorbents) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

HQE1:Germany

Address

305 College Road East, Princeton, NJ, USA, 08540

Website

https://www.cytosorbents.com

CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.

Executives

Edward Raymond Jones	director	70 HOGAN LANE, AMBLER PA 19002
Kathleen P. Bloch	officer: Chief Financial Officer	3 PERSHING COURT, NORTH BRUNSWICK NJ 08902
Vincent Capponi	officer: Chief Operating Officer	MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Phillip P. Chan	director, officer: President and CEO	1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Efthymios Deliargyris	officer: Chief Medical Officer	C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Jiny Kim	director	C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Alan D. Sobel	director	293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039
Michael G. Bator	director	C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852
Alex D'amico	officer: Chief Financial Officer	10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110
Al Kraus	director	MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Eric R. Mortensen	officer: Chief Medical Officer	C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Njtc Investment Fund, Lp	10 percent owner	1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Robert Shipley	10 percent owner	9 NOBLE ROAD, NOGALES AZ 85621
Ronald Berger	officer: See Remarks	7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852
Thomas Bocchino	officer: Chief Financial Officer	C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852